Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dihong Tang
Observed names:
D. Tang,
DIHONG TANG,
Di-Hong Tang,
Di-hong Tang
Institution:
Hunan Cancer Hospital
Observed institutions:
Central South University,
Hunan Cancer Hospital,
Xiangya Hospital Central South University,
Yiyang Medical College
ORCID:
0000-0003-1211-3726
Observed ORCID:
0000-0003-1211-3726
OpenAlex ID:
A5100595046
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
2022
·
Jifeng Feng
, Dihong Tang
, et al.
·
Clinical Cancer Research
·
67
MiR-218 produces anti-tumor effects on cervical cancer cells in vitro
2018
·
Li Zhu
, Huaidong Tu
, et al.
·
World Journal of Surgical Oncology
·
55
PDF
Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer
2020
·
Yang Peng
, Dihong Tang
, et al.
·
Cancer and Metastasis Reviews
·
50
Isolation, Culture and Identification of Choriocarcinoma Stem-Like Cells from the Human Choriocarcinoma Cell-Line JEG-3
2016
·
Jingting Cai
, Tianfang Peng
, et al.
·
Cellular Physiology and Biochemistry
·
26
Label-free detection of miRNA cancer markers based on terminal deoxynucleotidyl transferase-induced copper nanoclusters
2019
·
Yiting Li
, Dihong Tang
, et al.
·
Analytical Biochemistry
·
24
Diagnosis and multimodal therapy for extragastrointestinal stromal tumor of the prostate: A case report
2013
·
ZHENYU OU
, ZHENZHEN CAO
, et al.
·
Experimental and Therapeutic Medicine
·
16
PDF
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
2025
·
Jia Zhong
, Lin Wu
, et al.
·
Cancer Cell
·
14
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials.
2025
·
Xiaohua Wu
, Yaqing Chen
, et al.
·
Journal of Clinical Oncology
·
13
PDF
The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.
2024
·
Yutao Liu
, Guiling Li
, et al.
·
Journal of Clinical Oncology
·
13
PDF
Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer
2023
·
Xue Feng
, Xiaolin Meng
, et al.
·
Cancer Pathogenesis and Therapy
·
12
Single-cell profiling reveals the intratumor heterogeneity and immunosuppressive microenvironment in cervical adenocarcinoma
2024
·
Yang Peng
, Jing Yang
, et al.
·
eLife
·
11
PDF
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial
2024
·
Cheng Fang
, Yun Zhou
, et al.
·
Journal of Gynecologic Oncology
·
11
Isolation and comparison of mesenchymal stem cell-like cells derived from human gastric cancer tissues and corresponding ovarian metastases
2015
·
KUNYAN ZHOU
, MAN XIA
, et al.
·
Molecular Medicine Reports
·
10
PDF
Identification and characterization of a subpopulation of CD133+ cancer stem‐like cells derived from SK-UT-1 cells
2021
·
Jiuping Gao
, Ting Yang
, et al.
·
Cancer Cell International
·
7
PDF
Targeting Mitochondrial Cholesterol Efflux via TCF21/ABCA10 Pathway to Enhance Cisplatin Efficacy in Ovarian Cancer
2024
·
Li Li
, Hui Cheng
, et al.
·
Biochemical Genetics
·
4
Single-cell profiling reveals the intratumor heterogeneity and immunosuppressive microenvironment in cervical adenocarcinoma
2025
·
Yang Peng
, Jing Yang
, et al.
·
eLife
·
3
Single-cell profiling reveals the intratumor heterogeneity and immunosuppressive microenvironment in cervical adenocarcinoma
2024
·
Yang Peng
, Jing Yang
, et al.
·
eLife
·
2
Data from SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
2023
·
Jifeng Feng
, Dihong Tang
, et al.
·
2
Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
2026
·
Xiaohua Wu
, Rujiao Liu
, et al.
·
Journal of Clinical Oncology
·
1
1079P Biparatopic anti-HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum-refractory ovarian cancer (OC)
2025
·
X. Wu
, J. Li
, et al.
·
Annals of Oncology
·
1
Data from SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
2023
·
Jifeng Feng
, Dihong Tang
, et al.
·
1
179O A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
2022
·
J. Liu
, C. Fang
, et al.
·
Annals of Oncology
·
1
Study on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like Cells
2020
·
Jingting Cai
, Jiuping Gao
, et al.
·
1
PDF
[Analysis of the security, pregnancy outcomes, and the tumor recurrence related factors of young patients with cervical cancer treated with different radical trachelectomy].
2013
·
Yi-le Chen
, Le-sai Li
, et al.
·
PubMed
·
1
[Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
2008
·
Yi-Le Chen
, Yan-Qiong Liu
, et al.
·
PubMed
·
1
Show more works
View as search
Works count:
37
Citation count:
347
H-index:
11
I10-index:
13
Year
Topic
Type
